Treatment.com AI closes US$727.5K second debenture tranche
What's the deal? Treatment.com AIDealroom has a profile for this one. Try Dealroom →, operating as Rocket Doctor AI Inc., has closed the second tranche of an oversubscribed private placement of unsecured convertible debentures for US$727.5K. Together with the first tranche closed in August 2026, the offering has raised aggregate gross proceeds of US$2.39M. The post-IPO financing was announced on 17 August 2026.
The terms. The debentures carry 12.0% annual interest, calculated and payable at maturity 12 months after issuance. Holders can convert principal and accrued interest into units at US$0.51 each.
What's in a unit? Each unit combines one common share and one transferable warrant. Each warrant is exercisable into a share at US$0.55 for 12 months from issuance, subject to the company's acceleration right if its shares trade at US$0.55 or more on the Canadian Securities Exchange for 10 consecutive trading days.
Use of proceeds. The company intends to use the net proceeds for working capital and general and administrative expenses, primarily focused on its US growth plans. It paid US$42.2K in arm's-length finder fees in connection with the second tranche.
The signal. Convertible debentures let a listed company raise capital while deferring dilution until conversion. The second closing extends Rocket Doctor AI's funding for its US expansion while preserving the structure of the previously announced offering.
Read more: Financial Post
Image credit: www.ilmicrofono.it
